Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP21A2 | P08686 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069211 | 0.86 | MAOB (0.51) | MAOBPDE3BPDE3AESR1CYP3A4 | |
| SCHEMBL10069295 | 0.84 | INSR (0.40) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL13822181 | 0.82 | PDE3B (0.49) | MAOBPDE3BPDE3AESR1CYP3A4 | |
| SCHEMBL13127033 | 0.81 | MAOB (0.43) | MAOBPDE3BPDE3AESR1CYP3A4 | |
| SCHEMBL13126885 | 0.76 | ALOX5 (0.42) | MEN1KMT2AMAPTALOX15KDM4E | |
| SCHEMBL10069299 | 0.74 | NFE2L2 (0.41) | CYP3A4MEN1KMT2AMAPTKDM4E | |
| SCHEMBL8392726 | 0.74 | CYP3A4 (0.69) | MAOBPDE3BPDE3AESR1CYP3A4 | |
| SCHEMBL2604923 | 0.74 | CYP3A4 (0.69) | MAOBPDE3BPDE3AESR1CYP3A4 | |
| SCHEMBL13126892 | 0.73 | RAB9A (0.37) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10069303 | 0.73 | NFE2L2 (0.42) | MAOBMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124626-B2 | Methods of treating inflammations and infections with pyridinium salts | MYCOSOL, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7820696-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | KLEIN RICHARD B | 2010-10-21 | — | — | US | disclosed |
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | MYCOSOL, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7220761-B2 | Compounds and methods for controlling fungi, bacteria and insects | MYCOSOL, INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213299-A1 | COMPOUNDS AND METHODS FOR CONTROLLING FUNGI, BACTERIA AND INSECTS | BLVRB, PNPO, PLPBP | MAOB 102/4885PDE3B 1136/4885PDE3A 909/4885 |
| US-20100267716-A1 | METHODS OF TREATING INFLAMMATIONS AND INFECTIONS WITH PYRIDINIUM SALTS | PNPO, PLPBP, TPMT | MAOB 284/4885PDE3B 1103/4885PDE3A 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.